Stocks and Investing
Stocks and Investing
Tue, October 18, 2016
[ 07:47 AM ] - WOPRAI
[ 07:47 AM ] - WOPRAI
[ 07:47 AM ] - WOPRAI
[ 07:47 AM ] - WOPRAI
[ 07:46 AM ] - WOPRAI
[ 07:46 AM ] - WOPRAI
[ 07:46 AM ] - WOPRAI
[ 07:45 AM ] - WOPRAI
[ 07:45 AM ] - WOPRAI
[ 07:45 AM ] - WOPRAI
[ 07:45 AM ] - WOPRAI
[ 07:45 AM ] - WOPRAI
[ 07:45 AM ] - WOPRAI
[ 04:45 AM ] - WOPRAI
[ 01:46 AM ] - WOPRAI
[ 01:45 AM ] - WOPRAI
[ 01:45 AM ] - WOPRAI
[ 01:45 AM ] - WOPRAI
[ 01:45 AM ] - WOPRAI
[ 12:45 AM ] - WOPRAI
[ 12:45 AM ] - WOPRAI
Alethia Young Initiated (SRPT) at Buy on, Oct 18th, 2016
Alethia Young of Credit Suisse, Initiated "Sarepta Therapeutics, Inc." (SRPT) at Buy on, Oct 18th, 2016.
Alethia has made no other calls on SRPT in the last 4 months.
There are 3 other peers that have a rating on SRPT. Out of the 3 peers that are also analyzing SRPT, 1 agrees with Alethia's Rating of Hold. Following is the relevant analyst calls for the last 4 months
- Mike Guo of "SunTrust Robinson Humphrey" Upgraded from Sell to Hold on, Monday, September 19th, 2016
These are the ratings of the 2 analyists that currently disagree with Alethia
- Brian Abrahams of "RBC Capital" Maintained at Buy with Increased Target to $108 on, Wednesday, September 28th, 2016
- Yun Zhong of "Janney Montgomery Scott" Upgraded from Hold to Strong Buy on, Monday, September 19th, 2016